JP2016515515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515515A5 JP2016515515A5 JP2016502699A JP2016502699A JP2016515515A5 JP 2016515515 A5 JP2016515515 A5 JP 2016515515A5 JP 2016502699 A JP2016502699 A JP 2016502699A JP 2016502699 A JP2016502699 A JP 2016502699A JP 2016515515 A5 JP2016515515 A5 JP 2016515515A5
- Authority
- JP
- Japan
- Prior art keywords
- prlr antibody
- formulation
- prlr
- antibody formulation
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799629P | 2013-03-15 | 2013-03-15 | |
| US61/799,629 | 2013-03-15 | ||
| PCT/US2014/028078 WO2014143909A1 (en) | 2013-03-15 | 2014-03-14 | Anti-prolactin receptor antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016515515A JP2016515515A (ja) | 2016-05-30 |
| JP2016515515A5 true JP2016515515A5 (enExample) | 2017-04-13 |
Family
ID=50678293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502699A Pending JP2016515515A (ja) | 2013-03-15 | 2014-03-14 | 抗プロラクチン受容体抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9023357B2 (enExample) |
| EP (1) | EP2968538A1 (enExample) |
| JP (1) | JP2016515515A (enExample) |
| CN (1) | CN105025925A (enExample) |
| AR (1) | AR095496A1 (enExample) |
| CA (1) | CA2906101A1 (enExample) |
| HK (1) | HK1215175A1 (enExample) |
| TW (1) | TW201513882A (enExample) |
| UY (1) | UY35460A (enExample) |
| WO (1) | WO2014143909A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY171761A (en) | 2012-03-14 | 2019-10-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| UY35460A (es) * | 2013-03-15 | 2014-10-31 | Bayer Healthcare Llc | Formulaciones de anticuerpos anti-receptor de prolactina |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US11191844B2 (en) | 2015-07-06 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| MX2018007520A (es) | 2015-12-18 | 2018-08-01 | Astellas Pharma Inc | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. |
| IL249795B (en) * | 2016-02-05 | 2020-01-30 | Grifols Worldwide Operations Ltd | Intradermal administration of an immunoglobulin preparation g |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| CA3038894A1 (en) | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| US10925971B2 (en) | 2016-11-29 | 2021-02-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating PRLR positive breast cancer |
| MX2019010895A (es) * | 2017-03-16 | 2019-11-05 | Lg Chemical Ltd | Formulacion liquida de anticuerpo anti-tnf alfa. |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| KR102629972B1 (ko) * | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| EP3743088B1 (en) | 2018-01-26 | 2022-10-12 | F. Hoffmann-La Roche AG | Il-22 fc compositions and methods of use |
| IL276464B2 (en) | 2018-02-07 | 2026-01-01 | Regeneron Pharma | Methods and compositions for administering therapeutic protein |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CN120548195A (zh) | 2022-11-07 | 2025-08-26 | 上游生物公司 | 包含抗人类tslp受体抗体的药物组合物和其使用方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| HRP20140081T1 (hr) * | 2006-08-18 | 2014-03-28 | Novartis Ag | Prlr-specifiäśna antitijela i njihova uporaba |
| AU2007294575B2 (en) * | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| BRPI0721097A2 (pt) * | 2006-12-11 | 2014-07-01 | Hoffmann La Roche | Formulação parenteral de anticorpo abeta |
| CN101578113B (zh) * | 2007-01-11 | 2015-04-22 | 诺和诺德公司 | 抗-kir抗体、制剂及其应用 |
| WO2009055343A2 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| KR20140019035A (ko) * | 2008-09-19 | 2014-02-13 | 에프. 호프만-라 로슈 아게 | 신규한 항체 제형 |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| AU2010338305A1 (en) * | 2009-12-29 | 2012-05-24 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| UY35460A (es) * | 2013-03-15 | 2014-10-31 | Bayer Healthcare Llc | Formulaciones de anticuerpos anti-receptor de prolactina |
-
2014
- 2014-03-14 UY UY0001035460A patent/UY35460A/es not_active Application Discontinuation
- 2014-03-14 EP EP14722033.9A patent/EP2968538A1/en not_active Withdrawn
- 2014-03-14 AR ARP140101101A patent/AR095496A1/es unknown
- 2014-03-14 JP JP2016502699A patent/JP2016515515A/ja active Pending
- 2014-03-14 CA CA2906101A patent/CA2906101A1/en not_active Abandoned
- 2014-03-14 US US14/213,497 patent/US9023357B2/en active Active
- 2014-03-14 WO PCT/US2014/028078 patent/WO2014143909A1/en not_active Ceased
- 2014-03-14 TW TW103109457A patent/TW201513882A/zh unknown
- 2014-03-14 HK HK16103172.6A patent/HK1215175A1/zh unknown
- 2014-03-14 US US14/772,369 patent/US20160002342A1/en not_active Abandoned
- 2014-03-14 CN CN201480016050.7A patent/CN105025925A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515515A5 (enExample) | ||
| RU2015111319A (ru) | Препараты антитела к рецептору анти-пролактина | |
| RU2019100887A (ru) | Композиции антитела и белка | |
| JP2020518599A5 (enExample) | ||
| JP2019504086A5 (enExample) | ||
| RU2019138507A (ru) | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 | |
| RU2012131099A (ru) | Препарат антитела | |
| RU2016108652A (ru) | Способы лечения спорадического миозита с тельцами включений | |
| JP2020509031A5 (enExample) | ||
| JP2015526440A5 (enExample) | ||
| HRP20241526T1 (hr) | Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans | |
| JP2013518815A5 (enExample) | ||
| JP2011219478A5 (enExample) | ||
| PE20211453A1 (es) | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2014074046A5 (enExample) | ||
| NZ737046A (en) | Anti-cgrp antibody formulation | |
| JP2016508973A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| RU2015123476A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| JP2013543505A5 (enExample) | ||
| JP2013500947A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2015517489A5 (enExample) |